Vera Therapeutics, Inc. (VERA)
34.19
-0.41
(-1.18%)
USD |
NASDAQ |
Aug 28, 16:00
34.22
+0.03
(+0.09%)
After-Hours: 20:00
Vera Therapeutics Debt to Equity Ratio : 0.1845 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.1845 |
| March 31, 2026 | 0.1501 |
| December 31, 2025 | 0.1279 |
| September 30, 2025 | 0.1936 |
| June 30, 2025 | 0.1656 |
| March 31, 2025 | 0.1018 |
| December 31, 2024 | 0.0947 |
| September 30, 2024 | 0.19 |
| June 30, 2024 | 0.1611 |
| March 31, 2024 | 0.1506 |
| December 31, 2023 | 0.5282 |
| September 30, 2023 | 0.2386 |
| Date | Value |
|---|---|
| June 30, 2023 | 0.2141 |
| March 31, 2023 | 0.1945 |
| December 31, 2022 | 0.4068 |
| September 30, 2022 | 0.1148 |
| June 30, 2022 | 0.1001 |
| March 31, 2022 | 0.0951 |
| December 31, 2021 | 0.0707 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Oncolytics Biotech, Inc. | -0.0726 |
| Sangamo Therapeutics, Inc. | -1.020 |
| Sarepta Therapeutics, Inc. | 0.6845 |
| Anixa Biosciences, Inc. | 0.0127 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 532.98M |
| Total Liabilities (Quarterly) | 125.23M |
| Shareholders Equity (Quarterly) | 407.76M |
| Current Ratio | 10.65 |
| Net Debt Paydown Yield | -0.13% |